TRXADE HEALTH INC (MEDS) Fundamental Analysis & Valuation

NASDAQ:MEDS • US89846A4058

Current stock price

7.59 USD
+0.35 (+4.83%)
At close:
7.591 USD
+0 (+0.01%)
After Hours:

This MEDS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MEDS Profitability Analysis

1.1 Basic Checks

  • MEDS had negative earnings in the past year.
  • In the past year MEDS has reported a negative cash flow from operations.
  • In the past 5 years MEDS always reported negative net income.
  • MEDS had negative operating cash flow in 4 of the past 5 years.
MEDS Yearly Net Income VS EBIT VS OCF VS FCFMEDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

1.2 Ratios

  • MEDS has a Return On Assets of 28.09%. This is amongst the best in the industry. MEDS outperforms 97.44% of its industry peers.
  • MEDS has a Return On Equity of 35.39%. This is amongst the best in the industry. MEDS outperforms 97.44% of its industry peers.
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROIC N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
MEDS Yearly ROA, ROE, ROICMEDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

  • MEDS has a better Profit Margin (94.17%) than 97.44% of its industry peers.
  • The Operating Margin and Gross Margin are not available for MEDS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 94.17%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEDS Yearly Profit, Operating, Gross MarginsMEDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. MEDS Health Analysis

2.1 Basic Checks

  • MEDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MEDS has more shares outstanding
  • MEDS has a worse debt/assets ratio than last year.
MEDS Yearly Shares OutstandingMEDS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K
MEDS Yearly Total Debt VS Total AssetsMEDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

  • Based on the Altman-Z score of -2.40, we must say that MEDS is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.40, MEDS is doing worse than 61.54% of the companies in the same industry.
  • There is no outstanding debt for MEDS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.4
ROIC/WACCN/A
WACC11.3%
MEDS Yearly LT Debt VS Equity VS FCFMEDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M 6M 8M

2.3 Liquidity

  • MEDS has a Current Ratio of 4.18. This indicates that MEDS is financially healthy and has no problem in meeting its short term obligations.
  • MEDS's Current ratio of 4.18 is fine compared to the rest of the industry. MEDS outperforms 74.36% of its industry peers.
  • A Quick Ratio of 4.18 indicates that MEDS has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 4.18, MEDS is doing good in the industry, outperforming 79.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 4.18
MEDS Yearly Current Assets VS Current LiabilitesMEDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. MEDS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 63.73% over the past year.
  • MEDS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -53.03%.
  • Measured over the past years, MEDS shows a quite strong growth in Revenue. The Revenue has been growing by 16.65% on average per year.
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MEDS Yearly Revenue VS EstimatesMEDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
MEDS Yearly EPS VS EstimatesMEDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2020 2021 2022 2023 2024 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MEDS Valuation Analysis

4.1 Price/Earnings Ratio

  • MEDS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MEDS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MEDS Price Earnings VS Forward Price EarningsMEDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEDS Per share dataMEDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. MEDS Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 125.16%, MEDS is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.59, MEDS pays a better dividend. On top of this MEDS pays more dividend than 100.00% of the companies listed in the same industry.
  • MEDS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.89.
Industry RankSector Rank
Dividend Yield 125.16%

5.2 History

  • MEDS does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MEDS Yearly Dividends per shareMEDS Yearly Dividends per shareYearly Dividends per share 2024 2 4 6 8

5.3 Sustainability

DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
MEDS Yearly Income VS Free CF VS DividendMEDS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 0 -5M -10M -15M

More info and screens

Find the best dividend stocksShow peers with best dividend

MEDS Fundamentals: All Metrics, Ratios and Statistics

TRXADE HEALTH INC

NASDAQ:MEDS (9/20/2024, 8:07:08 PM)

After market: 7.591 +0 (+0.01%)

7.59

+0.35 (+4.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)07-22
Earnings (Next)N/A
Inst Owners0.02%
Inst Owner Change0%
Ins Owners309.26%
Ins Owner Change0%
Market Cap11.08M
Revenue(TTM)4.43M
Net Income(TTM)4.17M
Analysts82.86
Price Target6.89 (-9.22%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 125.16%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-99.59%
Min Revenue beat(2)-100%
Max Revenue beat(2)-99.18%
Revenue beat(4)0
Avg Revenue beat(4)-53.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-1.65%
Revenue beat(8)1
Avg Revenue beat(8)-31.56%
Revenue beat(12)5
Avg Revenue beat(12)-13.38%
Revenue beat(16)7
Avg Revenue beat(16)-4.94%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.5
P/FCF N/A
P/OCF N/A
P/B 0.94
P/tB 0.94
EV/EBITDA N/A
EPS(TTM)-2.29
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-6.71
FCFYN/A
OCF(TTM)-5.1
OCFYN/A
SpS3.03
BVpS8.07
TBVpS8.07
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 28.09%
ROE 35.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 94.17%
GM N/A
FCFM N/A
ROA(3y)-109.37%
ROA(5y)-71.82%
ROE(3y)-1295.91%
ROE(5y)-784.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 4.18
Altman-Z -2.4
F-Score4
WACC11.3%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.17%
EPS Next Y57.14%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-53.03%
Revenue growth 3Y-21.53%
Revenue growth 5Y16.65%
Sales Q2Q%-99.17%
Revenue Next Year4.1%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-909.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year54.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-168.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.13%
OCF growth 3YN/A
OCF growth 5YN/A

TRXADE HEALTH INC / MEDS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for TRXADE HEALTH INC?

ChartMill assigns a fundamental rating of 3 / 10 to MEDS.


What is the valuation status for MEDS stock?

ChartMill assigns a valuation rating of 0 / 10 to TRXADE HEALTH INC (MEDS). This can be considered as Overvalued.


Can you provide the profitability details for TRXADE HEALTH INC?

TRXADE HEALTH INC (MEDS) has a profitability rating of 2 / 10.


Can you provide the financial health for MEDS stock?

The financial health rating of TRXADE HEALTH INC (MEDS) is 6 / 10.